Our results underscore the value of pinpointing crucial molecular characteristics in the pursuit of novel modulators of the ERCC1–XPF interaction, which could be combined with cisplatin to treat NSCLC more effectively. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.